Clinical Trials · NCT00627796
Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- Federico II University
- Enrollment
- 27
- Start date
- Jan 2003
- Locations
- 1 site, Italy
- Primary endpoint
- Control of GH and IGF-I excess and tumor shrinkage